125 related articles for article (PubMed ID: 23479363)
1. Composite three-marker assay for early detection of kidney cancer.
Su Kim D; Choi YD; Moon M; Kang S; Lim JB; Kim KM; Park KM; Cho NH
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):390-8. PubMed ID: 23479363
[TBL] [Abstract][Full Text] [Related]
2. Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma.
Kim DS; Ham WS; Jang WS; Cho KS; Choi YD; Kang S; Kim B; Kim KJ; Lim EJ; Rha SY; Ku JH; Kwak C; Kim HH; Jeong CW; Cho NH
Diagnostics (Basel); 2020 Sep; 10(10):. PubMed ID: 32992891
[TBL] [Abstract][Full Text] [Related]
3. Panel of candidate biomarkers for renal cell carcinoma.
Kim DS; Choi YP; Kang S; Gao MQ; Kim B; Park HR; Choi YD; Lim JB; Na HJ; Kim HK; Nam YP; Moon MH; Yun HR; Lee DH; Park WM; Cho NH
J Proteome Res; 2010 Jul; 9(7):3710-9. PubMed ID: 20455597
[TBL] [Abstract][Full Text] [Related]
4. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.
Roessler M; Rollinger W; Palme S; Hagmann ML; Berndt P; Engel AM; Schneidinger B; Pfeffer M; Andres H; Karl J; Bodenmüller H; Rüschoff J; Henkel T; Rohr G; Rossol S; Rösch W; Langen H; Zolg W; Tacke M
Clin Cancer Res; 2005 Sep; 11(18):6550-7. PubMed ID: 16166432
[TBL] [Abstract][Full Text] [Related]
5. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
6. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
7. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
9. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test.
Sartini D; Muzzonigro G; Milanese G; Pozzi V; Vici A; Morganti S; Rossi V; Mazzucchelli R; Montironi R; Emanuelli M
Cell Biochem Biophys; 2013 Apr; 65(3):473-83. PubMed ID: 23097023
[TBL] [Abstract][Full Text] [Related]
11. Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma.
Sartini D; Muzzonigro G; Milanese G; Pierella F; Rossi V; Emanuelli M
J Urol; 2006 Nov; 176(5):2248-54. PubMed ID: 17070307
[TBL] [Abstract][Full Text] [Related]
12. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
Weinberger R; Appel B; Stein A; Metz Y; Neheman A; Barak M
Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
[TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique.
Chinello C; Gianazza E; Zoppis I; Mainini V; Galbusera C; Picozzi S; Rocco F; Galasso G; Bosari S; Ferrero S; Perego R; Raimondo F; Bianchi C; Pitto M; Signorini S; Brambilla P; Mocarelli P; Galli Kienle M; Magni F
Urology; 2010 Apr; 75(4):842-7. PubMed ID: 19963255
[TBL] [Abstract][Full Text] [Related]
14. Serum M65 as a biomarker for metastatic renal cell carcinoma.
Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
[TBL] [Abstract][Full Text] [Related]
15. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
[TBL] [Abstract][Full Text] [Related]
16. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
17. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.
Hauser S; Zahalka T; Fechner G; Müller SC; Ellinger J
Anticancer Res; 2013 Oct; 33(10):4651-6. PubMed ID: 24123044
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide
Holstein S; Venz S; Junker H; Walther R; Stope MB; Zimmermann U
Anticancer Res; 2019 Oct; 39(10):5427-5436. PubMed ID: 31570437
[TBL] [Abstract][Full Text] [Related]
19. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
20. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
